Topics:
Thoracic Malignancies • Medical Oncology • NCI-CCC Tumor Board Question • Ohio State University
How would you approach a patient with metastatic squamous NSCLC that progressed on carbo/paclitaxel/pembro and has a FGFR3 S249C mutation?
Especially if you don't have trials available at the moment.
Would you try off-label erdafitinib (given recent data on bladder cancer) or 2nd line gemcitabine monotherapy?
Answer from: Medical Oncologist at Community Practice
It is unclear if erda will have efficacy here in nsclc. If no trial available can consider gem while working on potential off label if patient interested, though there is an ongoing study looking at this, which would be best option.
Sign in or Register to read more